RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression

Cancer Letters

Volumn 311, Issue 1, 2011, Pages 48-56

  Cho, Hee Jun ^a   Baek, Kyoung Eun ^a   Park, Sun Mi ^a   Kim, In Kyu ^a   Nam, In Koo ^a   Choi, Yeong Lim ^a   Park, Seung Ho ^a   Im, Min Ju ^a   Choi, Jungil ^b   Ryu, Jinhyun ^b   Kim, Jae Won ^a   Lee, Chang Won ^a   Kang, Sang Soo ^b   Yoo, Jiyun ^a  

^a Gyeongsang National University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

Author keywords

Bcl 2; Cisplatin; Gastric cancer; RhoGDI2

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; RHO GDP DISSOCIATION INHIBITOR 2; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STAUROSPORINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; STAUROSPORINE; STOMACH NEOPLASMS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

MUS MUSCULUS;

EID: 80052179360     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.024     Document Type: Article

References (41)

1. Barocas D.A., Clark P.E. Bladder cancer. Curr. Opin. Oncol. 2008, 20:307-314.
2. Ferraldeschi R., Baka S., Jyoti B., Faivre-Finn C., Thatcher N., Lorigan P. Modern management of small-cell lung cancer. Drugs 2007, 67:2135-2152.
3. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7:573-584.
4. Moehler M., Galle P.R., Gockel I., Junginger T., Schmidberger H. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancer. Best Pract. Res. Clin. Gastroenterol. 2007, 21:965-981.
5. Yuan J.N., Chao Y., Lee W.P., Li C.P., Lee R.C., Chang F.Y., Yen S.H., Lee S.D., Whang-Peng J. Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Med. Oncol. 2008, 25:201-206.
6. Andrews P.A., Jones J.A., Varki N.M., Howell S.B. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun. 1990, 2:93-100.
7. Dovas A., Couchman J.R. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem. J. 2005, 390:1-9.
8. DerMardirossian C., Bokoch G.M. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 2005, 15:356-363.
9. Hart M.J., Maru Y., Leonard D., Witte O.N., Evans T., Cerione R.A. A GDP dissociation inhibitor that serves as a GTPase inhibitor for the Ras-like protein CDC42Hs. Science 1992, 258:812-815.
10. Chuang T.H., Xu X., Knaus U.G., Hart M.J., Bokoch G.M. GDP dissociation inhibitor prevents intrinsic and GTPase activating protein-stimulated GTP hydrolysis by the Rac GTP-binding protein. J. Biol. Chem. 1993, 268:775-778.
11. Fukomoto Y., Kaibuchi K., Hori Y., Fujioka H., Araki S., Ueda T., Kikuchi A., Takai Y. Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the Rho proteins, ras p21-like small GTP-binding proteins. Oncogene 1990, 5:1321-1328.
12. Scherle P., Behrens T., Staudt L.M. Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc. Natl Acad. Sci. USA 1993, 90:7568-7572.
13. Zalcman G., Closson V., Camonis J., Honoré N., Rousseau-Merck M.F., Tavitian A., Olofsson B. RhoGDI-3 is a new GDP dissociation inhibitor (GDI). Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins RhoB and RhoG. J. Biol. Chem. 1996, 271:30366-30374.
14. Lelias J.M., Adra C.N., Wulf G.M., Guillemot J.C., Khagad M., Caput D., Lim B. cDNA cloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissociation inhibitor for the rho GTP-binding proteins. Proc. Natl Acad. Sci. USA 1993, 90:1479-1483.
15. Adra C.N., Manor D., Ko J.L., Zhu S., Horiuchi T., Van Aelst L., Cerione R.A., Lim B. RhoGDIγ: a GDP-dissociation inhibitor for Rho proteins with preferential expression in brain and pancreas. Proc. Natl Acad. Sci. USA 1997, 94:4279-4284.
16. Zhang Y., Rivera Rosado L.A., Moon S.Y., Zhang B. Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signalling. J. Biol. Chem. 2009, 284:12956-12965.
17. Moissoglu K., McRoberts K.S., Meier J.A., Theodorescu D., Schwartz M.A. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res. 2009, 69:2838-2844.
18. Gildea J.J., Seraj M.J., Oxford G., Harding M.A., Hampton G.M., Moskaluk C.A., Frierson H.F., Conaway M.R., Theodorescu D. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002, 62:6418-6423.
19. Theodorescu D., Sapinoso L.M., Conaway M.R., Oxford G., Hampton G.M., Frierson H.F. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin. Cancer Res. 2004, 10:3800-3806.
20. Tapper J., Kettunen E., El-Rifai W., Seppala M., Andersson L.C., Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet. Cytogenet. 2001, 128:1-6.
21. Zhang Y., Zhang B. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res. 2006, 66:5592-5598.
22. Cho H.J., Baek K.Y., Park S.M., Kim I.K., Choi Y.L., Cho H.J., Nam I.K., Hwang E.M., Park J.Y., Han J.Y., Kang S.S., Kim D.C., Lee W.S., Lee M.N., Oh G.T., Kim J.W., Lee C.W., Yoo J. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer. Clin. Cancer Res. 2009, 15:2612-2619.
23. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
24. Yin L., Schwartzberg P., Scharton-Kersten T.M., Staudt L., Lenardo M. Immune responses in mice deficient in Ly-GDI, a lymphoid-specific regulator of Rho GTPases. Mol. Immunol. 1997, 34:484-491.
25. Seraj M.J., Harding M.A., Gildea J.J., Welch D.R., Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin. Exp. Metastasis 2000, 18:519-525.
26. Cho H.J., Baek K.Y., Yoo J. RhoGDI2 as a therapeutic target in cancer. Expert Opin. Ther. Targets 2010, 14:67-75.
27. Zhang B., Zhang Y., Dagher M.C., Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res. 2005, 65:6054-6062.
28. Essmann F., Wieder T., Otto A., Muller E.C., Dorken B., Daniel P.T. GDP dissociation inhibitor D4-GDI, but not the homologous RhoGDI1, is cleaved by caspase-3 during drug-induced apoptosis. Biochem. J. 2000, 346:777-783.
29. Sun D., Xu D., Zhang B. Rac signaling in tumorigenesis and as target for anticancer drug development. Drug Resist. Updates 2006, 9:274-287.
30. Bromberg Y., Shani E., Joseph G., Gorzalczany Y., Sperling O., Pick E. The GDP-bound form of the small G protein Rac1 p21 is a potent activator of the superoxide-forming NADPH oxidase of macrophages. J. Biol. Chem. 1994, 269:7055-7058.
31. Lin Q., Fuji R.N., Yang W., Cerione R.A. RhoGDI is required for Cdc42-mediated cellular transformation. Curr. Biol. 2003, 13:1469-1479.
32. Groysman M., Hornstein I., Alcover A., Katzav S. Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducer in T cell antigen receptor-induced pathways. J. Biol. Chem. 2002, 277:50121-50130.
33. Cho H.J., Kim J.K., Kim K.D., Yoon H.K., Cho M.Y., Park Y.P., Jeon J.H., Lee E.S., Byun S.S., Lim H.M., Song E.Y., Lim J.S., Yoon D.Y., Lee H.G., Choe Y.K. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett. 2006, 237:56-66.
34. Michaud W.A., Nichols A.C., Mroz E.A., Faquin W.C., Clark J.R., Begum S., Westra W.H., Wada H., Busse P.M., Ellisen L.W., Rocco J.W. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 2009, 15:1645-1654.
35. Losert D., Pratscher B., Soutschek J., Geick A., Vornlocher H.P., Müller M., Wacheck V. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel. Anticancer Drugs 2007, 18:755-761.
36. Kim R., Emi M., Tanabe K., Toge T. Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer 2004, 101:2177-2186.
37. Sharma H., Sen S., Lo Muzio L., Mariggiò A., Singh N. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol. Ther. 2005, 4:720-727.
38. Warmann S.W., Frank H., Heitmann H., Ruck P., Herberts T., Seitz G., Fuchs J. Bcl-2 gene silencing in pediatric epithelial liver tumors. J. Surg. Res. 2008, 144:43-48.
39. Zheng Z., Li J., He X., Chen X., Yu B., Ji J., Zhang J., Wang T., Gu Q., Zhu Z., Liu B. Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil. Hepatogastroenterology 2010, 57:1106-1112.
40. Yip K.W., Reed J.C. Bcl-2 family proteins and cancer. Oncogene 2008, 27:6398-6406.
41. Reed J.C. Bcl-2 family proteins and hematologic malignancies: histology and future prospects. Blood 2008, 111:3322-3330.